Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.

Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, ...

African American patients with newly diagnosed multiple myeloma were less likely than White patients to receive drugs that ...

As fly fishing became less like a hobby and more like a lifeline, could a retreat help ease my emotional burden?

A woman with multiple myeloma, a rare blood cancer that develops in plasma cells in the bone marrow, says a new immunotherapy ...

When we say "the risk is reduced," what exactly is being reduced?Imagine an elderly person diagnosed with multiple myeloma ...

A contract dispute between my health system and insurer has left me worried about losing access to care. I'm hardly the only ...

When can we answer the question, "Is the treatment working?"After a few courses of treatment for multiple myeloma have passed, many patients likely wonder, "Is this treatment actually working?"The ...

Exploring T-Cell Engager Therapy for Multiple Myeloma - Moffitt Cancer Center / cancer, Cell Coast 2026, Ken Shain, Moffitt ...

A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...

Bristol Myers Squibb (BMY) on Thursday announced that it succeeded in a Phase 3 trial for a combination regimen containing Zenbexus, a treatment already available in the U.S. under the FDA’s ...